Analytical Control of Darunavir Tablet Dosage Forms. Part I.
- 作者: Goizman M.1, Korlyukov A.2, Suponitskii K.2, Shimanovskii N.3, Popova T.1, Popova A.1, Glotova O.1, Zotova O.1, Tikhomirova G.1
-
隶属关系:
- Drug Technology Co.
- A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
- N. I. Pirogov National Research Medical University
- 期: 卷 51, 编号 11 (2018)
- 页面: 1030-1036
- 栏目: Structure of Chemical Compounds, Methods of Analysis and Process Control
- URL: https://journals.rcsi.science/0091-150X/article/view/244897
- DOI: https://doi.org/10.1007/s11094-018-1734-4
- ID: 244897
如何引用文章
详细
Purposeful development of special methods to be included into pharmacopoeial monographs on the quality of darunavir (DRV) preparations is shown to allow the use of expensive imported standard samples (SSs) for drug analysis to be avoided. Part I of the present work describes these methods and their validation. UV spectrophotometry is proposed in the “Authenticity” section for detecting DRV by the coincidence of extrema in the spectrum of an aqueous MeOH extract (pH 9) with well-known peaks in the spectrum of deprotonated DRV at 230 nm (minimum) and 267 nm (maximum). This section also requires GC analysis for solvated EtOH, the presence of which indicates that DRV ethanolate was used as the active pharmaceutical ingredient (API) and the absence of which, that non-solvated amorphous DRV was used. The significant increase in the accuracy of the quantitative determination and the sharp reduction in its duration allow the use of SSs to be avoided. For this reason, the “Dissolution” section proposes determining the DRV concentration in the dissolution medium (pH 3) by spectrophotometry using a method that requires experimental determination of the specific absorption coefficient \( \left({A}_{1\mathrm{cm}}^{1\%}\right) \) of DRV solutions in this medium at the maximum (267 nm). The established value \( \left({A}_{1\mathrm{cm}}^{1\%}\right. \) = (393.4 ± 2) cm–1 was a physicochemical constant with a relative standard deviation RSD < 1% at confidence level α = 0.05.
作者简介
M. Goizman
Drug Technology Co.
编辑信件的主要联系方式.
Email: goizmanmi@gmail.com
俄罗斯联邦, 2a Rabochaya St., Khimki, Moscow Oblast, 141400
A. Korlyukov
A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
Email: goizmanmi@gmail.com
俄罗斯联邦, 28 Vavilova St., Moscow, 119991
K. Suponitskii
A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
Email: goizmanmi@gmail.com
俄罗斯联邦, 28 Vavilova St., Moscow, 119991
N. Shimanovskii
N. I. Pirogov National Research Medical University
Email: goizmanmi@gmail.com
俄罗斯联邦, 1 Ostrovityanova St., Moscow, 117997
T. Popova
Drug Technology Co.
Email: goizmanmi@gmail.com
俄罗斯联邦, 2a Rabochaya St., Khimki, Moscow Oblast, 141400
A. Popova
Drug Technology Co.
Email: goizmanmi@gmail.com
俄罗斯联邦, 2a Rabochaya St., Khimki, Moscow Oblast, 141400
O. Glotova
Drug Technology Co.
Email: goizmanmi@gmail.com
俄罗斯联邦, 2a Rabochaya St., Khimki, Moscow Oblast, 141400
O. Zotova
Drug Technology Co.
Email: goizmanmi@gmail.com
俄罗斯联邦, 2a Rabochaya St., Khimki, Moscow Oblast, 141400
G. Tikhomirova
Drug Technology Co.
Email: goizmanmi@gmail.com
俄罗斯联邦, 2a Rabochaya St., Khimki, Moscow Oblast, 141400